AIM ImmunoTech AIM Stock
AIM ImmunoTech Price Chart
AIM ImmunoTech AIM Financial and Trading Overview
| AIM ImmunoTech stock price | 0.09 USD |
| Previous Close | 0.46 USD |
| Open | 0.47 USD |
| Bid | 0.45 USD x 3000 |
| Ask | 0.5 USD x 900 |
| Day's Range | 0.46 - 0.5 USD |
| 52 Week Range | 0.29 - 0.89 USD |
| Volume | 87.5K USD |
| Avg. Volume | 89.74K USD |
| Market Cap | 23.91M USD |
| Beta (5Y Monthly) | -0.296126 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.92 USD |
AIM Valuation Measures
| Enterprise Value | -7225250 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.0977777 |
| PEG Ratio (5 yr expected) | -0.04 |
| Price/Sales (ttm) | 152.31656 |
| Price/Book (mrq) | 0.696756 |
| Enterprise Value/Revenue | -46.021 |
| Enterprise Value/EBITDA | 0.348 |
Trading Information
AIM ImmunoTech Stock Price History
| Beta (5Y Monthly) | -0.296126 |
| 52-Week Change | -39.50% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.89 USD |
| 52 Week Low | 0.29 USD |
| 50-Day Moving Average | 0.47 USD |
| 200-Day Moving Average | 0.5 USD |
AIM Share Statistics
| Avg. Volume (3 month) | 89.74K USD |
| Avg. Daily Volume (10-Days) | 87.02K USD |
| Shares Outstanding | 48.41M |
| Float | 47.5M |
| Short Ratio | 10.63 |
| % Held by Insiders | 1.88% |
| % Held by Institutions | 11.06% |
| Shares Short | 706.92K |
| Short % of Float | 1.48% |
| Short % of Shares Outstanding | 1.45% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:44 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -13417.83% |
| Gross Margin | 149.04% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -28.74% |
| Return on Equity (ttm) | -43.68% |
Income Statement
| Revenue (ttm) | 157K USD |
| Revenue Per Share (ttm) | 0.003 USD |
| Quarterly Revenue Growth (yoy) | 48.50% |
| Gross Profit (ttm) | N/A |
| EBITDA | -20792000 USD |
| Net Income Avi to Common (ttm) | -19286000 USD |
| Diluted EPS (ttm) | -0.38 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 30.85M USD |
| Total Cash Per Share (mrq) | 0.64 USD |
| Total Debt (mrq) | 814K USD |
| Total Debt/Equity (mrq) | 2.33 USD |
| Current Ratio (mrq) | 18.051 |
| Book Value Per Share (mrq) | 0.709 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -17030000 USD |
| Levered Free Cash Flow (ttm) | -7850250 USD |
Profile of AIM ImmunoTech
| Country | United States |
| State | FL |
| City | Ocala |
| Address | 2117 SW Highway 484 |
| ZIP | 34473 |
| Phone | (352) 448-7797 |
| Website | https://aimimmuno.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 22 |
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Q&A For AIM ImmunoTech Stock
What is a current AIM stock price?
AIM ImmunoTech AIM stock price today per share is 0.09 USD.
How to purchase AIM ImmunoTech stock?
You can buy AIM shares on the NYSE American exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for AIM ImmunoTech?
The stock symbol or ticker of AIM ImmunoTech is AIM.
Which industry does the AIM ImmunoTech company belong to?
The AIM ImmunoTech industry is Biotechnology.
How many shares does AIM ImmunoTech have in circulation?
The max supply of AIM ImmunoTech shares is 68.75M.
What is AIM ImmunoTech Price to Earnings Ratio (PE Ratio)?
AIM ImmunoTech PE Ratio is 0.00000000 now.
What was AIM ImmunoTech earnings per share over the trailing 12 months (TTM)?
AIM ImmunoTech EPS is 0 USD over the trailing 12 months.
Which sector does the AIM ImmunoTech company belong to?
The AIM ImmunoTech sector is Healthcare.
AIM ImmunoTech AIM included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NYSE AMEX COMPOSITE INDEX XAX | 4960.67 USD — |
+0.3
|
— — | — — | — — | — - | — — |
- {{ link.label }} {{link}}